Linerixibat
CAS No. : 1345982-69-5
(Synonyms: GSK2330672)
| Size | Price | Stock |
|---|---|---|
| 1mg | $100 | In-stock |
| 5mg | $270 | In-stock |
| 10mg | $450 | In-stock |
| 25mg | $744 | In-stock |
| 50mg | $1080 | In-stock |
| 100mg | $1512 | In-stock |
| 200 mg | Get quote | |
| 500 mg | Get quote | |
| We match the lowest price on market. | ||
We offer a substantial discount on larger orders, please inquire via [email protected]
or Fax: (86)21-58955996
Inquiry for price and availability only. Please place your order via our email or fax.
| Cat. No. : | HY-16643 |
| M.Wt: | 546.68 |
| Formula: | C28H38N2O7S |
| Purity: | >98 % |
| Solubility: | DMSO : 50 mg/mL (ultrasonic) |
Linerixibat (GSK2330672) is a highly potent, nonabsorbable and orally active apical sodium-dependent bile acid transporter (ASBT) inhibitor with an IC50 of 42 nM human ASBT. Linerixibat can be used as lipid-lowering agent. Linerixibat has the potential for type 2 diabetes and Primary Biliary Cholangitis treatment[1][2][3]. IC50 & Target:IC50: 42 nM (Apical sodium-dependent bile acid transporter (ASBT))[1] In Vitro:The zwitterionic, nonhygroscopic, crystalline salt form of Linerixibat (Compound 56) shows good aqueous solubility at pH 7.4 (>7 mg/mL), excellent thermal stability, and did not generate reactive or humanspecific metabolite, characteristics[1]. In Vivo:Linerixibat (GSK2330672; 0.05-10 mg/kg; oral gavage; twice daily; for 14 days; male ZDF rat) treatment lowers glucose in an animal model of type 2 diabetes[1].
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Autem earum hic iste maiores, nam neque rem suscipit. Adipisci consequatur error exercitationem fugit ipsam optio qui, quibusdam repellendus sed vero! Debitis.
Inquiry Information- Product Name:
- Linerixibat
- Cat. No.:
- HY-16643
- Quantity:
Your information is safe with us.